Aug 15, 2022 4:05pm EDT Sonnet BioTherapeutics Provides Fiscal Year 2022 Third Quarter Business and Earnings Update
Jul 22, 2022 7:00am EDT Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy
Jul 21, 2022 7:30am EDT Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers
Jun 09, 2022 7:00am EDT Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition
Jun 02, 2022 9:25am EDT Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum
May 10, 2022 8:15am EDT Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update
Apr 13, 2022 7:00am EDT Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors
Apr 08, 2022 1:05pm EDT Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research (AACR) 2022 Annual Meeting
Mar 16, 2022 7:00am EDT Sonnet BioTherapeutics Announces FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid Tumors
Feb 09, 2022 6:30am EST Sonnet BioTherapeutics Announces Abstract Accepted for Presentation in a Poster Session at the AACR 2022 Annual Meeting
